IN THE UNITED STATES	
FOR THE DISTRICT OF	MASSACHUSETTS
ABIOMED, INC.,)
Plaintiff)
-VS-) CA No. 16-10914-FDS
MAQUET CARDIOVASCULAR LLC,) Pages 1 - 15)
Defendant)
STATUS CONFE	RENCE
BEFORE THE HONORABLE F. DENNIS SAYLOR, IV UNITED STATES DISTRICT JUDGE	
	ed States District Court urthouse Way, Courtroom 2
Bost	on, Massachusetts 02210 1, 2017, 3:00 p.m.
	_,,
LEE A. MARZILL OFFICIAL COURT REP	
United States Distric	t Court
Boston, MA 022 (617)345-6787	10
	FOR THE DISTRICT OF ABIOMED, INC., Plaintiff -VS- MAQUET CARDIOVASCULAR LLC, Defendant STATUS CONFE BEFORE THE HONORABLE F. UNITED STATES DIST United States District 1 Courthouse Way, Row Boston, MA 022

Page 1 of 16 ABIOMED Ex. 1055

APPEARANCES: MICHAEL KENDALL, ESQ., White & Case, LLP, 75 State Street, 24th Floor, Boston, Massachusetts, 02109, for the Plaintiff. SCOTT T. WEINGAERTNER, ESQ. and JOHN PADRO, ESQ., White & Case, LLP, 1221 Avenue of the Americas, New York, New York, 10020, for the Plaintiff. MICHAEL S. CONNOR, ESQ. and TRAVIS IAMS, ESQ., Alston & Bird LLP, Bank of America Plaza, 101 South Tyron Street, Suite 4000, Charlotte, North Carolina, 28280-4000, for the Defendant. MICHAEL J. DERDERIAN, ESQ., Pierce Atwood LLP, 100 Summer Street, 22nd Floor, Boston, Massachusetts, 02110, for the Defendant.

Page 2 of 16 ABIOMED Ex. 1055

1 PROCEEDINGS 2 THE CLERK: Court is now in session on the matter 3 of Abiomed v. Maquet Cardiovascular LLC, Civil Action 4 No. 16-10914. Will counsel please identify themselves for 5 the record. MR. KENDALL: Yes, good afternoon, your Honor. 6 7 White & Case for Abiomed. I'm Mike Kendall. MR. PADRO: I'm John Padro. 8 9 MR. WEINGAERTNER: Good afternoon, your Honor. 10 Scott Weingaertner for Abiomed. 11 THE COURT: All right, good afternoon. 12 MR. CONNOR: Good afternoon, your Honor. Mike 13 Connor for defendant, Maquet Cardiovascular. 14 MR. IAMS: Travis Iams, also representing Maquet Cardiovascular. 15 16 MR. DERDERIAN: And Michael Derderian representing 17 Maquet. 18 THE COURT: All right, good afternoon. All right, this is a status conference in this case. The parties 19 20 submitted what I guess is a form of joint statement of 2.1 issues that they say I ought to be thinking about. Why don't I start, I'll give you the floor, Mr. Weingaertner. 2.2 23 MR. WEINGAERTNER: Yes, your Honor. So, your 24 Honor, one of the issues that we had discussed when we first 25 met in January had to do with the expansion of the case by

Page 3 of 16 ABIOMED Ex. 1055

Maquet, Maquet being the patentee and we're the DJ plaintiff. And they had patents that were pending that had not been added to the case; they had been issuing. We had understood they would possibly be added by March. They haven't been yet. And we understand, although relatively recently, that Maquet does intend to add them, but we have no schedule right now, your Honor, for amending them and our response. And that timing also affects some ongoing procedures that we have now; namely, invalidity contentions and noninfringement contentions which we're kind of in the middle of having to deal with on the first three patents. So Maquet has added to those contentions three patents that are not yet in the case.

THE COURT: These are all continuation patents?

MR. WEINGAERTNER: Yes, your Honor, although they have many claims. There's hundred claims, or well over a hundred claims. So what we were hoping was that we could invoke your Honor's assistance in trying to get a schedule for the amendment, and then our answer and any counterclaims or any defenses that we have, and then rethink the schedule, because a couple of months have gone by based upon what we thought was going to be the schedule originally, so that we have time, adequate time to prepare what is in essence a case that's going to be twice as large as the existing case.

THE COURT: All right, why don't we take this one

Page 4 of 16 ABIOMED Ex. 1055

1 issue at a time. Who's going to take the lead, Mr. Connor? MR. CONNOR: Your Honor, this is Mike Connor. 2 3 Your Honor, our position is that there is no surprise to 4 Abiomed about the nature of the case or the inclusion of 5 these additional patents. So prior to the CMC, the parties 6 submitted a joint statement. The joint statement recognized 7 that there were three patents already in the case, there are three continuation applications that would issue, and that 9 all were agreed by both parties should be included in this 10 case. The schedule that was proposed to the Court and 11 entered by the Court acknowledges, had that in mind, your 12 Honor, that all six patents would be included in the case. 13 According to that schedule, Maquet served its preliminary 14 infringement contentions on May the 25th for all six of the 15 patents, regardless of the pleading issue. So, your Honor, 16 all of the disclosures that had been provided are the same 17 that would otherwise be, regardless of the pleading issue. 18 So this is really a matter of form over substance, your Honor. Abiomed has known of these continuation applications 19 2.0 since at least December of last year. Within a day or two 2.1 of issuance, we --2.2 THE COURT: I mean -- I'm sorry -- have you 23 already served your infringement contentions? 24 MR. CONNOR: Yes, as to all six. 25 THE COURT: As to all six, okay, the three

Page 5 of 16 ABIOMED Ex. 1055

existing and the three to be added?

2.

2.0

2.1

2.2

MR. CONNOR: Yes, that's correct, your Honor, and so they know the claims that are at issue. They know the basis for the infringement positions. They are in full possession of information that they would be entitled to for purposes of their invalidity and noninfringement contentions, which are due July the 28th under the schedule the Court entered when the parties contemplated all six as being in the case.

I should say, so I think that the pleading issue is really a matter of form over substance as to the three additional patents.

THE COURT: If that's true, is there any reason we can't get this done? In other words, you move to amend the complaint to add the three new complaints, they can respond, and then --

MR. CONNOR: There's absolutely no reason, your Honor. I will tell you that we will do it within the next three weeks. The reason it hasn't been done already is the reason that we discussed at the CMC, which was to avoid duplicative or multiple amendments to the complaint. That was discussed at the CMC. At the time we knew that some patents were issuing sooner than others, and the question was, well, should we file multiple amendments or just file one? And the discussion was, well, let's just do one

Page 6 of 16 ABIOMED Ex. 1055

amendment for efficiency.

2.0

2.1

2.2

Our client has been investigating whether to assert some nonpatent counterclaims in this case, and we would propose to do it all in one filing. We have now essentially completed that investigation and intend to file the amended pleading within the next two weeks.

The schedule that your Honor has entered does not address any nonpatent issues, your Honor. It's limited really to the Markman -- I guess the invalidity contentions and the Markman process.

THE COURT: All right, I guess what I would propose is, I set a deadline for a filing of a motion to amend, and if you can say you can do it in two weeks, how about if I set it for two weeks out? You'll have a chance to respond. We'll see, you know, whether there are counterclaims, you know, different contentions; and if the schedule needs to be changed, I'll try to be reasonable about it. I would like to try to hold this Markman hearing in November, just because my schedule may quickly go downhill shortly thereafter, but let's see where we are, or October, whenever I set it but the fall.

MR. WEINGAERTNER: Your Honor, we disagree with Mr. Connor's characterization of what's happened so far.

There was no reason that the complaint couldn't have been amended earlier. In calls that we've had about other

Page 7 of 16 ABIOMED Ex. 1055

issues, the issue was raised, and we were told that they can't respond about whether or when they're going to add them. And so it put us in a really unusual position about whether we will need to litigate patents, really complex patents that aren't in the case. And now we're in a position, your Honor, where if the schedule doesn't change, we're going to basically be forced to respond to a doubled case while we're responding and not knowing whether or not the schedule will be --

2.2

THE COURT: All right, and, again, to me, it's kind of abstract because I don't know. You may be right; you may not be right. This may double the size of the case; it may not. I can't tell. So let's take it a step at a time. Let's get this amended complaint on file, assuming I grant it. Let's circle back in some appropriate amount of time, probably in about 30 days, and see where we are.

MR. WEINGAERTNER: Okay, just, your Honor, just to note that I believe the contentions that we have to respond to are due at the end of July.

THE COURT: Okay. Well, I think he just said that this is not going to add any new contentions. Now, that may or may not be true, but if I see you in 30 days, that will give you another 30 days. In other words, I'm not going to be doing this at the last second. We'll have a chance to talk about this. And if you think it's not fair, you know,

Page 8 of 16 ABIOMED Ex. 1055

we'll talk about that.

2.

2.0

2.1

2.2

MR. WEINGAERTNER: Thank you.

THE COURT: Again, as I see my role here, it's to try to keep this case moving along without being unfair or unreasonable, and sometimes I have to tweak the schedule and sometimes not, but I can't tell. So let's handle it that way. I'm going to set a deadline. Today is June the 1st. Filing of motions to amend by June the 15th. And just so that I don't forget it, why don't we have a further status -- is July 5 a problem, the day after the 4th of July? You can appear by telephone. I don't require you to be here in person.

MR. WEINGAERTNER: No problem.

MR. CONNOR: That's fine, your Honor.

THE COURT: All right, I don't want anybody on a plane on the 4th if you don't need to be. How about 11:00 a.m., Wednesday, July 5? And that's just a status to see where we are, and if there's an issue, I'll deal with it.

Okay, next issue. Mr. Weingaertner?

MR. WEINGAERTNER: Yes, your Honor. When we had prepared this, there were some open issues, and we were awaiting to hear a response from Maquet. We heard from them yesterday on an issue. We're hoping that we'll be able to resolve these without the Court's intervention, but we did

Page 9 of 16 ABIOMED Ex. 1055

feel --

2.

2.1

2.2

THE COURT: Is this discovery or supplementation?

MR. WEINGAERTNER: Yes, your Honor, we believe

that there are some discovery issues. One of them actually
is sort of related to the following point, which if I might

mention it. So Maquet is the patent owner. As far as we

know, it doesn't practice the patents, although we haven't
gotten a straight answer on that one, but we believe that
its parent company, which appears to have some offices in
the U.S., is a potential real party-in-interest, and we
spoke about that with your Honor in January. So we're

trying to get some discovery on that.

We have other discovery about value. They have actually acquired the patents in the first instance, and we believe there is discoverable information probably relatively targeted, and so we have been trying to work with Maquet to find kind of an efficient way to get that, and we haven't been able to arrive at that yet. And we're --

THE COURT: Is the issue because the -- is it a foreign company? Is it overseas evidence?

MR. WEINGAERTNER: Yes, your Honor. It's in Sweden.

THE COURT: Sweden, all right.

MR. WEINGAERTNER: Although we believe that there are offices in the U.S. that also operate on behalf of

Page 10 of 16 ABIOMED Ex. 1055

Maquet.

2.1

2.2

THE COURT: Okay. My strong recommendation is, if you need to go to Sweden, do it in the next few months and not next winner. Okay?

MR. CONNOR: Your Honor, there are a number of discovery matters that are pending in dispute between the parties. Our part of the letter had a Paragraph 2. Similarly, we have issues with them. We have offered to meet and confer on all of that essentially. We proposed, your Honor, that both parties do need to -- I think both parties need to be producing documents, need to be supplementing interrogatory answers. We would propose that the parties attempt to work that out in the next 30 days, and then at the status conference, your Honor, we could seek your Honor's guidance, if it's needed at that time.

And, you know, to state the obvious, I want you to meet and confer. I want you to try to work it out. Sometimes you can't work it out. That's the way it is. Sometimes it depends on legal rulings I need to make, sometimes not, but I'd like to just get the process rolling; you know, if you have a dispute, get it teed up. If we're going to have to do, you know, Hague Conventions, you know, if we're going to have to do this sort of stuff, let's get that going because that's going to take a long time, and I just want to make

Page 11 of 16 ABIOMED Ex. 1055

```
headway on this to try to crystallize this as best we can.
 1
 2.
     So we'll start with a meet-and-confer, work out what you can
 3
     work out, and report back to me in early July where we are.
 4
     If you need to file a motion to compel or a protective
 5
     order, file it; let's get it on file and take it from there,
 6
     okay?
 7
               MR. CONNOR: Yes, your Honor.
               MR. WEINGAERTNER: Yes, your Honor.
 9
               MR. CONNOR: Thank you.
10
                THE COURT: All right. And what about IPR, or
11
     there may be other issues as well? Mr. Weingaertner?
12
               MR. WEINGAERTNER: Yes, your Honor, we just wanted
13
     to keep the Court apprised of the status of the patents.
14
     Abiomed filed fourteen petitions. The number is in part
15
     dictated by the word limits that the Patent Office's Patent
16
     and Trial Appeal Board imposes. Those were filed --
17
                THE COURT: So you're deliberately attempting to
18
     evade the word limits? Are you saying that on the record
19
     here?
2.0
                (Laughter.)
2.1
               MR. WEINGAERTNER: It's impermissible to do that,
2.2
     but -- it's tempting, but, no, it's really dictated by the
     numerosity of the claims. There's very many claims and
23
24
     they're very long, and you have to pay a fee each time, so
25
     we hope that from their perspective, it comes out in the
```

Page 12 of 16 ABIOMED Ex. 1055

wash. But we filed those some weeks ago. Those are in. We expect -- Maquet must respond within three months of the filing of each of those, and then within six months the Patent and Trademark Office decides whether or not to initiate a proceeding, and so we simply wanted to keep the Court apprised of that.

2.2

THE COURT: And my view on that again, maybe simplistically, is, until they do it, this case is alive. If they do grant inter partes review, you know, whether I stay it or not or whatever, we'll just see. And I understand there is mixed — in other words, this wouldn't take into account all the claims anyway. At least that's Maquet's position, I think, right?

MR. CONNOR: Correct, your Honor.

MR. WEINGAERTNER: That's right, your Honor. And we absolutely understand your Honor's position and simply wanted to be sure that we're being clear about it. If and when the time comes that they're instituted, we'll bring it up in a status conference.

THE COURT: Okay, and, again, that's one more bridge or set of bridges we'll cross when the time comes.

MR. CONNOR: I think that's fine, your Honor. I just wanted to note, I mean, it's interesting that they've come in and said that they need time to develop invalidity positions, when in fact with the IPR petitions, they filed

Page 13 of 16 ABIOMED Ex. 1055

about five feet high full of petitions and so on, so --1 MR. WEINGAERTNER: Well, your Honor, just to 2. 3 respond to that, the positions that can be taken before the 4 Patent Office are entirely different from the ones --5 they're overlapping but they're much different from the defenses we can pursue in court, so I don't agree that's a 6 7 fair characterization of the case. THE COURT: All right, well, we'll see. 8 9 don't try to evade my word limits, okay? 10 MR. WEINGAERTNER: No, your Honor. 11 THE COURT: Or page limits I guess is how I do it. 12 In all seriousness, if we get to -- as long as I raised the 13 topic, I'll finish the thought. My view is, if you need 30 14 or 40 or 50 pages to do something, I'll give it to you, but 15 don't waste my time or waste paper. You know, I understand 16 sometimes these things are complicated. All I ask is, 17 picture me reading your material, that's all, and then 18 reading your opposition and the reply and the surreply and the cross-motions. You know, I have to read this stuff, 19 2.0 so --2.1 MR. WEINGAERTNER: I have nothing, your Honor. THE COURT: Okay. 2.2 23 MR. CONNOR: Nothing further, your Honor. 24 THE COURT: All right, so we'll regroup in about a 25 Again, you can appear by telephone. Again, there's month.

Page 14 of 16 ABIOMED Ex. 1055

```
no need for you to fly over a holiday weekend. I just want
1
2
     to check in, see where we are, whether I need to tweak
3
     deadlines, set motion hearings and so forth. I probably
 4
     told you at the scheduling conference, I do like status
     conferences in the sense that I think they tend to help move
5
     things along; and if there's a lot of moving parts, as there
6
7
     may well be here, at least for a little, you know, we'll
     just keep conferring and try to steer it the right
8
9
     direction, okay?
10
               All right, unless there's anything else, thank
11
     you.
                             Thank you, your Honor.
12
               MR. CONNOR:
13
               MR. WEINGAERTNER: Thank you, your Honor.
14
                (Adjourned, 3:15 p.m.)
15
16
17
18
19
20
21
22
23
24
25
```

Page 15 of 16 ABIOMED Ex. 1055

```
1
                           C \ E \ R \ T \ I \ F \ I \ C \ A \ T \ E
 2
 3
     UNITED STATES DISTRICT COURT )
 4
     DISTRICT OF MASSACHUSETTS
                                       SS.
     CITY OF BOSTON
 5
 6
 7
                I, Lee A. Marzilli, Official Federal Court
     Reporter, do hereby certify that the foregoing transcript,
 8
 9
     Pages 1 through 15 inclusive, was recorded by me
10
     stenographically at the time and place aforesaid in Civil
11
     Action No. 16-10914-FDS, Abiomed, Inc. V. Maquet
     Cardiovascular LLC, and thereafter by me reduced to
12
13
     typewriting and is a true and accurate record of the
14
     proceedings.
15
                 Dated this 11th day of June, 2017.
16
17
18
19
                      /s/ Lee A. Marzilli
20
21
                      LEE A. MARZILLI, CRR
                      OFFICIAL COURT REPORTER
22
23
24
25
```

Page 16 of 16 ABIOMED Ex. 1055